<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03088150</url>
  </required_header>
  <id_info>
    <org_study_id>NL58551.029.16</org_study_id>
    <nct_id>NCT03088150</nct_id>
  </id_info>
  <brief_title>COLLISION Trial - Colorectal Liver Metastases: Surgery vs Thermal Ablation</brief_title>
  <acronym>COLLISION</acronym>
  <official_title>COLLISION Trial - Colorectal Liver Metastases: Surgery vs Thermal Ablation, a Phase III Single-blind Prospective Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VU University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic - MITG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>VU University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to prove non-inferiority of thermal ablation compared to hepatic&#xD;
      resection in patients with at least one resectable and ablatable colorectal liver metastases&#xD;
      (≤3cm) and no extrahepatic disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design:&#xD;
&#xD;
      COLLISION is a single-blind prospective multi-center phase-III randomized controlled trial.&#xD;
      We hypothesize that thermal ablation is non-inferior to surgery for the selected patient&#xD;
      groups in terms of the primary objective (overall survival). The Cox proportional hazards&#xD;
      model (1-sided; non-inferiority or superiority) is used for sample size calculations. Given&#xD;
      the superior safety profile we consider a hazard ratio of 1.3 to represent the upper limit of&#xD;
      non-inferiority (non-inferiority margin). An HR of 1.3 corresponds to a 56.5% chance of the&#xD;
      ablated patients to die first ((P = HR/(1 + HR) = 1.3/(1 + 1.3) = 0.565 (56.5%)). With 3&#xD;
      years of patient accrual and five years of follow-up we will have reached 60% of events&#xD;
      (death) in approximately 6.5 years (overall probability of event, pE =0.6). The calculated&#xD;
      sample size therefore is 599 (NS).To account for a 10% drop-out ratio (NDO=69) prior to&#xD;
      randomization and a 3% loss to follow-up (NLTFU=18) after randomization we need to include&#xD;
      687 patients (NI). A total number of 618 patients will be randomized (NR) into one of two&#xD;
      arms: arm A will undergo surgical resection (n=309) and arm B thermal ablation (n=309) for&#xD;
      appointed target lesions.&#xD;
&#xD;
      Study population:&#xD;
&#xD;
      Patients with ≥1 resectable and ablatable CRLM (≤3cm), no extrahepatic disease and a good&#xD;
      performance status (WHO 0-2) are considered eligible. Supplementary resections for resectable&#xD;
      lesions &gt;3cm and thermal ablations for unresectable CRLM ≤3cm are allowed with a maximum&#xD;
      number of CRLM of 10.&#xD;
&#xD;
      Intervention:&#xD;
&#xD;
      Eligible patients will be stratified into low-, intermediate- and high disease burden after&#xD;
      assessment by an expert panel. The panel, consisting of at least two diagnostic radiologists,&#xD;
      two interventional radiologists and two hepatobiliary and/or oncological surgeons, will&#xD;
      appoint lesions that are resectable and ablatable as target lesions, resectable and&#xD;
      unablatable lesions as unablatable lesions and ablatable but unresectable lesions as&#xD;
      unresectable lesions. All unablatable lesions should be resectable and all unresectable&#xD;
      lesions should be ≤3cm and ablatable.&#xD;
&#xD;
      With the exception of patients that are suitable for laparoscopic resection or percutaneous&#xD;
      ablation (low disease burden), eligibility needs to be reconfirmed during the surgical&#xD;
      procedure. Hereafter patients will be randomized to undergo surgical resection of the target&#xD;
      lesions (allowing thermal ablation for additional unresectable lesions) or thermal ablation&#xD;
      (allowing resection for additional unablatable lesions). For open procedures randomization&#xD;
      will be performed shortly after surgical inspection and IOUS with the patient under general&#xD;
      anaesthesia. Both the experimenter(s) and the participant will be unaware of the eventual&#xD;
      treatment arm prior to the procedure; after the procedure the patient will remain unaware&#xD;
      (single-blind).&#xD;
&#xD;
      Conferring to national guidelines follow-up will include imaging, laboratory tests including&#xD;
      tumour markers (CEA) and clinical examination every 3 months for the first year and every 6&#xD;
      months hereafter. Follow-up cross-sectional imaging should include at least an abdominal ceCT&#xD;
      or upper abdominal ceMRI at the given time-points. Participating centres are free to add&#xD;
      18F-FDG PET-CTs at specific time-points or to use alternating specific modalities, as long as&#xD;
      the follow-up protocol is pre-approved by the trial coordinators and as long as follow-up&#xD;
      imaging is identical for both treatment arms. Quality of life questionnaires will be assessed&#xD;
      at baseline, every 3 months for the first year and every 6 months hereafter accordingly.&#xD;
&#xD;
      Patients with recurrences that are considered unsuitable for additional focal therapy will be&#xD;
      re-referred to their medical oncologist to assess additional systemic chemotherapy. In the&#xD;
      event of chemotherapeutic down-staging hereafter, focal therapy can be reconsidered.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 13, 2017</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>5 years</time_frame>
    <description>Counting from the date of randomization to the date of death of the patient or to the last day of follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>5 years</time_frame>
    <description>The time from focal therapy to the time of events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>5 years</time_frame>
    <description>The time from focal therapy to the time of events.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">618</enrollment>
  <condition>ColoRectal Cancer</condition>
  <condition>Liver Metastasis Colon Cancer</condition>
  <condition>Liver Metastases</condition>
  <condition>Surgery</condition>
  <arm_group>
    <arm_group_label>Surgical resection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients included will undergo resection of hepatic metastases, allowing thermal ablation for additional unresectable lesions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Thermal ablation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients included will undergo ultrasound guided thermal ablation of hepatic metastases, allowing resection for additional unablatable lesions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Thermal ablation</intervention_name>
    <description>Patients will undergo either radiofrequency ablation (RFA) or microwave ablation (MWA).</description>
    <arm_group_label>Thermal ablation</arm_group_label>
    <other_name>Radiofrequency ablation</other_name>
    <other_name>RFA</other_name>
    <other_name>Microwave ablation</other_name>
    <other_name>MWA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgical resection</intervention_name>
    <description>In case of randomization to surgical resection, the surgeon will remove all target lesions as well as all additional unablatable lesions.</description>
    <arm_group_label>Surgical resection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Most important inclusion criteria:&#xD;
&#xD;
          -  At least one CRLM size ≤ 3 cm eligible for both surgical resection and thermal&#xD;
             ablation (target lesions);&#xD;
&#xD;
          -  Additional unresectable CRLM should be ≤ 3 cm and ablatable (unresectable lesions);&#xD;
&#xD;
          -  Additional unablatable CRLM should be resectable (unablatable lesions);&#xD;
&#xD;
          -  Maximum number of CRLM 10;&#xD;
&#xD;
          -  Resectability and ablatability should be re-confirmed intra-operatively by US plus&#xD;
             full exploration for hepatic, peritoneal and regional lymph node metastases;&#xD;
&#xD;
          -  ASA 1-3.&#xD;
&#xD;
        Most important exclusion criteria:&#xD;
&#xD;
          -  No target lesions suitable for both resection and ablation;&#xD;
&#xD;
          -  Radical treatment unfeasible or unsafe (e.g. insufficient FLR);&#xD;
&#xD;
          -  The presence of extrahepatic nodal or non-nodal metastases;&#xD;
&#xD;
          -  Immunotherapy or chemotherapy ≤ 6 weeks prior to the procedure;&#xD;
&#xD;
          -  Any surgical resection or focal ablative liver therapy for CRLM prior to inclusion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MR Meijerink, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VU University Medical Center, Amsterdam, NL</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>RS Puijk, MD</last_name>
    <phone>020 444 4444</phone>
    <email>interventieradiologie@vumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>MR Meijerink, MD, PhD</last_name>
    <phone>020 444 4444</phone>
    <email>interventieradiologie@vumc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Amsterdam University Medical Center - location VUmc</name>
      <address>
        <city>Amsterdam</city>
        <state>NH</state>
        <zip>1081</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M.R. Meijerink, MD, PhD</last_name>
      <phone>0204444444</phone>
      <email>interventieradiologie@vumc.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>January 11, 2017</study_first_submitted>
  <study_first_submitted_qc>March 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2017</study_first_posted>
  <last_update_submitted>August 27, 2019</last_update_submitted>
  <last_update_submitted_qc>August 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>VU University Medical Center</investigator_affiliation>
    <investigator_full_name>Dr. M.R. Meijerink</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <keyword>Hepatic resection</keyword>
  <keyword>Liver surgery</keyword>
  <keyword>Thermal ablation</keyword>
  <keyword>Radiofrequency ablation</keyword>
  <keyword>Microwave ablation</keyword>
  <keyword>RFA</keyword>
  <keyword>MWA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

